

October 11, 2005

To Whom It May Concern:

Yoshiji KIMURA
President and Chief Executive Officer
MEDINET Co., Ltd.
(TSE-Mothers #2370)
2-5-14, Shin-Yokohama, Kohoku-ku,
Yokohama, Kanagawa, Japan
Tel: +81 (0)45-478-0041 (Switch Board)
Email: ir@medinet-inc.co.jp

**Immuno-Cell Therapy Total Support Service to “22nd Century Medical
and Research Center” in the University of Tokyo Hospital**

MEDINET Co., Ltd. (“MEDINET”) and the University of Tokyo Hospital (“Todai Hospital”) have reached agreement on October 11, 2005 that MEDINET will provide “Immuno-Cell Therapy Total Support Service” with Todai Hospital and that “Center for Immune Cell Therapy (“CICT”)” with Cell Processing Center (“CPC”) will be established in the “22nd Century Medical and Research Center,” which will be completed as a part of a new Central Unit of Hospital in March 2006.

“Department of Immunotherapeutics (MDINET)” at Todai Hospital, settled by donation from MEDINET and commenced June 2004, has been implementing basic researches and clinical studies for Immuno-Cell Therapy based upon molecular immunological studies in order to clarify the positioning of this medical technology in the area of cancer therapies and to establish a basis of the therapy as a prevailed technology. After the completion of 22nd Century Medical and Research Center, the Department will change the place of its activities to CICT and will make implementation of clinical studies for not only existing Immuno-Cell Therapies such as Activated Autologous Lymphocyte Therapy and Dendritic Cell Therapy but new medical treatment technologies of various protocols including combined methods with other therapies against various types of cancers. As the result of those studies, medical treatment technologies, in which efficacy and safety are confirmed, will be provided with patients accordingly at Todai Hospital.

We are convinced that full-fledged activities towards Immuno-Cell Therapy by Todai Hospital, realized under this agreement will be the driving force to establish EBM (Evidence Based Medicine) for Immuno-Cell Therapy and to be diffused as the medical treatment familiar with the public.

Based upon Basic Operating Agreement dated on October 11, 2005, we will proceed planning, designing and practicing of CICT and will make arrangement of

This is an abridged translation of abstract of MEDINET’s press. MEDINET made its best efforts to translate with accuracy but it does not mean the translation is the same description as the original.

This press release was created for the purpose of providing information that will help investors make informed decisions. It was not created to solicit investors to buy or sell MEDINET’s share. The final decision and responsibility for investments rests solely with the user of this release and its content. Furthermore, opinions, forecasts and other content found on this release are based on assumptions and beliefs of MEDINET at the time of preparation. While every effort is made to ensure the accuracy of information described on this release, MEDINET assumes no responsibility, whatsoever, for any losses resulting from the use of this release or its description.

implementation plan after commencement of operation. Detailed information including expected influences to operating result will be announced once confirmed.

【22nd Century Medical and Research Center】

The Project of 22nd Century Medical and Research Center is the project implemented by Todai Hospital in order to make R&D for new medical science and medical related services. The Center is recognized as one of units of advanced medical development research cluster. The Project set a target that R&D achievement of the Project will be provided to patient in a short time. In the fiscal year of 2006, a base for the Project will be transferred to “22nd Century Medical and Research Center” in new Central Unit of Hospital (Phase II).

Summary: new Central Unit of Hospital (Phase II)

Completion: March 2006

Area: circa. 30,000m²

1. Medical Care Unit (B3 – 7th floor)

Operating Room, Radio diagnosis/Radiotherapy, Physical examination, Perinatal period care for mothers and children, Rehabilitation, Pathological examination, Tissues Bank, CPC, etc.

2. 22nd Century Medical and Research Center (8th/9th floor; 6,000m²)

- 1) Preventive medicine Health related services/business
- 2) Clinical trial study/business
- 3) Drug discovery related study
- 4) Medical related education study/business
- 5) Incubation business
- 6) Others – Medical services study/development and etc.

22nd Century Medical and Research Center – image of facility



This is an abridged translation of abstract of MEDINET’s press. MEDINET made its best efforts to translate with accuracy but it does not mean the translation is the same description as the original.

This press release was created for the purpose of providing information that will help investors make informed decisions. It was not created to solicit investors to buy or sell MEDINET’s share. The final decision and responsibility for investments rests solely with the user of this release and its content. Furthermore, opinions, forecasts and other content found on this release are based on assumptions and beliefs of MEDINET at the time of preparation. While every effort is made to ensure the accuracy of information described on this release, MEDINET assumes no responsibility, whatsoever, for any losses resulting from the use of this release or its description.

i) Immuno-Cell Therapy Total Support Service

Comprehensive services to provide technologies, know-how, facilities/devices, materials, skilled cell engineers, information systems and etc. to medical institutions in order to implement Immuno-Cell Therapy with safe and efficient manner.

ii) Activated autologous lymphocyte therapy

The therapy to eliminate abnormal cells in vivo with lymphocyte cultured in vitro and activated/proliferated with lymphocytes of patients themselves, by putting back into the body of original patients, which play a central role in immunoreactions directly to attack and eliminate cancer cells. This therapy has little side-effect or nothing with using lymphocyte of patients themselves and it can be used in combination with standardized therapies such as surgical therapy, chemotherapy and radiotherapy during any phases. Therefore this therapy becomes taken into account as one of the options of most advanced cancer therapies.

iii) Dendritic Cell (DC) therapy

The therapy to eliminate cancer cells, with guide of specifically cancer-cell attacking T-lymphocyte to which dendritic cell with utilizing cancerous tissue of patents tell information of cancer cells (antigen presentation) – T-lymphocyte plays main role in cancer immune. Dendritic cell is the cell to command the attack with passing antigen as the marker of cancer cell to T-Lymphocyte. If T-lymphocytes are soldiers to battle against enemies, Dendritic cells play the role of the commander.

This is an abridged translation of abstract of MEDINET's press. MEDINET made its best efforts to translate with accuracy but it does not mean the translation is the same description as the original.

This press release was created for the purpose of providing information that will help investors make informed decisions. It was not created to solicit investors to buy or sell MEDINET's share. The final decision and responsibility for investments rests solely with the user of this release and its content. Furthermore, opinions, forecasts and other content found on this release are based on assumptions and beliefs of MEDINET at the time of preparation. While every effort is made to ensure the accuracy of information described on this release, MEDINET assumes no responsibility, whatsoever, for any losses resulting from the use of this release or its description.